Today we learned that Lilly will close their Singapore R&D facility. This facility was focused on drug discovery in cancer and diabetes. I leave it to the powers that be…
It is regrettable that the FDA issued a complete response letter to Jazz Pharmaceuticals for JZP-6. If there is a disease that can use some innovation, it's fibromyalgia. The CRL…
Physicians typically don't interact with their patients via email. This is understandable and quite interesting, as physicians tend to be quite computer savvy. A recent report explains the reasons why this is the case.
Drug delivery is not dead! In fact, drug delivery can ba a valuable tool for developing and commercializing drugs faster and at lower cost versus NCEs.
Late last month, Johnson and Johnson (J&J) announced the results of Phase III clinical trials comparing tapentadol extended release compared to oxycodone controlled release and placebo. In this study, J&J…
Today we read the news that GSK will spin out a team of fourteen scientists and patents into a standalone company. Convergence Pharmaceuticals will focus on the development of pain…
Chronic pain patients have to wait even longer for access to twice-daily tapentadol.
It's certainly interesting to consider Latin American countries from a US perspective. Aside from the friendlier time differences, transportation and logistics could be simpler, as the article suggests. From a…
Today we hear the news that Covance has done it again. Today they acquired two European R&D sites from Sanofi for $25 million. In addition, Sanofi agreed to purchase R&D…
Welcome to my new blog and web site! Lacerta Bio has been organized to provide a range of pharmaceutical and biotechnology business development services. Please visit our About page to…